1-6 of 6
Mark-David Levin
Close
Sort by
Journal Articles

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Clinical Trials & Observations
Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2024) 8 (2): 388–398.
https://doi.org/10.1182/bloodadvances.2023010579
Published: 2024
Includes: Supplemental data
Journal Articles

COVID-19 vaccination in patients with immune thrombocytopenia

Clinical Trials & Observations
Chantal Visser, Maurice Swinkels, Erik D. van Werkhoven, F. Nanne Croles, Heike S. Noordzij-Nooteboom, Matthijs Eefting, Suzanne M. Last-Koopmans, Cecile Idink, Peter E. Westerweel, Bart Santbergen, Pieter A. Jobse, Fazil Baboe, RECOVAC-IR Consortium, Peter A. W. te Boekhorst, Frank W. G. Leebeek, Mark-David Levin, Marieke J. H. A. Kruip, A. J. Gerard Jansen
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1637–1644.
https://doi.org/10.1182/bloodadvances.2021006379
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy and safety of daratumumab combined with all- trans retinoic acid in relapsed/refractory multiple myeloma

Clinical Trials & Observations
Kristine A. Frerichs, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M. J. Bos, Marie José Kersten, Tuna Mutis, Christie P. M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5128–5139.
https://doi.org/10.1182/bloodadvances.2021005220
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

Clinical Trials & Observations
Rowan Kuiper, Sonja Zweegman, Mark van Duin, Martin H. van Vliet, Erik H. van Beers, Belinda Dumee, Michael Vermeulen, Jasper Koenders, Bronno van der Holt, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, H. Berna Beverloo, Marian Stevens-Kroef, Mark-David Levin, Annemiek Broijl, Anders Waage, Pieter Sonneveld
Journal: Blood Advances
Blood Adv (2020) 4 (24): 6298–6309.
https://doi.org/10.1182/bloodadvances.2020002838
Published: 2020
Includes: Supplemental data
Journal Articles

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Clinical Trials & Observations
Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B. M. Remmerswaal, Frederike J. Bemelman, Carsten U. Niemann, Sabina Kersting, Mark-David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2642–2652.
https://doi.org/10.1182/bloodadvances.2019000360
Published: 2019
Includes: Supplemental data
Journal Articles

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Clinical Trials & Observations
Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, Mark-David Levin
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3566–3571.
https://doi.org/10.1182/bloodadvances.2018019422
Published: 2018
Includes: Supplemental data